Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine

T. J. Benedetti; S. N. Caritis; W. J. Ledger; N. H. Lauersen; J. M. Moutquin; S. B. Effer; J. C. Sinclair; R. S. Sauve; R. A. Milner; K. J. Leveno; F. G. Cunningham

doi:10.1056/NEJM199212103272414

Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine

T. J. Benedetti, S. N. Caritis, W. J. Ledger, N. H. Lauersen, J. M. Moutquin, S. B. Effer, J. C. Sinclair, R. S. Sauve, R. A. Milner, K. J. Leveno, F. G. Cunningham

Research output: Contribution to journal › Letter › peer-review

83 Scopus citations

Abstract

To the Editor: In the Canadian study of ritodrine (July 30 issue),¹ no mention is made of the power of the study to detect meaningful differences. I have calculated its statistical power for the major outcome variables and have found there to be serious problems with the conclusion reached by both the study authors and the editorialists, Leveno and Cunningham² — i.e., that there are no significant differences between the treatment groups. The observed mortality in both groups was 6 percent. If there were a true reduction in mortality by 50 percent (from 6 percent to 3 percent) in the…

Original language	English (US)
Pages (from-to)	1758-1760
Number of pages	3
Journal	New England Journal of Medicine
Volume	327
Issue number	24
DOIs	https://doi.org/10.1056/NEJM199212103272414
State	Published - Dec 10 1992

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199212103272414

Cite this

@article{33e8fe1812914a9884bc9f44f04063e7,

title = "Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine",

abstract = "To the Editor: In the Canadian study of ritodrine (July 30 issue),1 no mention is made of the power of the study to detect meaningful differences. I have calculated its statistical power for the major outcome variables and have found there to be serious problems with the conclusion reached by both the study authors and the editorialists, Leveno and Cunningham2 — i.e., that there are no significant differences between the treatment groups. The observed mortality in both groups was 6 percent. If there were a true reduction in mortality by 50 percent (from 6 percent to 3 percent) in the…",

author = "Benedetti, {T. J.} and Caritis, {S. N.} and Ledger, {W. J.} and Lauersen, {N. H.} and Moutquin, {J. M.} and Effer, {S. B.} and Sinclair, {J. C.} and Sauve, {R. S.} and Milner, {R. A.} and Leveno, {K. J.} and Cunningham, {F. G.}",

year = "1992",

month = dec,

day = "10",

doi = "10.1056/NEJM199212103272414",

language = "English (US)",

volume = "327",

pages = "1758--1760",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine

AU - Benedetti, T. J.

AU - Caritis, S. N.

AU - Ledger, W. J.

AU - Lauersen, N. H.

AU - Moutquin, J. M.

AU - Effer, S. B.

AU - Sinclair, J. C.

AU - Sauve, R. S.

AU - Milner, R. A.

AU - Leveno, K. J.

AU - Cunningham, F. G.

PY - 1992/12/10

Y1 - 1992/12/10

N2 - To the Editor: In the Canadian study of ritodrine (July 30 issue),1 no mention is made of the power of the study to detect meaningful differences. I have calculated its statistical power for the major outcome variables and have found there to be serious problems with the conclusion reached by both the study authors and the editorialists, Leveno and Cunningham2 — i.e., that there are no significant differences between the treatment groups. The observed mortality in both groups was 6 percent. If there were a true reduction in mortality by 50 percent (from 6 percent to 3 percent) in the…

AB - To the Editor: In the Canadian study of ritodrine (July 30 issue),1 no mention is made of the power of the study to detect meaningful differences. I have calculated its statistical power for the major outcome variables and have found there to be serious problems with the conclusion reached by both the study authors and the editorialists, Leveno and Cunningham2 — i.e., that there are no significant differences between the treatment groups. The observed mortality in both groups was 6 percent. If there were a true reduction in mortality by 50 percent (from 6 percent to 3 percent) in the…

UR - http://www.scopus.com/inward/record.url?scp=0026447743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026447743&partnerID=8YFLogxK

U2 - 10.1056/NEJM199212103272414

DO - 10.1056/NEJM199212103272414

M3 - Letter

C2 - 1435925

AN - SCOPUS:0026447743

SN - 0028-4793

VL - 327

SP - 1758

EP - 1760

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Treatment of Preterm Labor with the Beta-Adrenergic Agonist Ritodrine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this